J Korean Med Sci.  2020 Sep;35(38):e337. 10.3346/jkms.2020.35.e337.

Vaccine-related Anaphylaxis Cases Confirmed by KCDC from 2001–2016

  • 1Department of Pediatrics, Sun General Hospital, Daejeon, Korea
  • 2Department of Pediatrics, Incheon Medical Center, Incheon, Korea
  • 3Department of Pediatrics, Chungnam National University, College of Medicine, Daejeon, Korea
  • 4Division of Vaccine-Preventable Disease Control and National Immunization Program, Korea Centers for Disease Control and Prevention, Cheongju, Korea


A national immunization program (NIP) to prevent disease and reduce mortality from vaccine preventable diseases (VPD) is very important.
We analyzed only the anaphylaxis cases that occurred between 2001 and 2016 that Korea Centers for Disease Control and Prevention (KCDC) determined had a definite causal relationship with a vaccine. The clinical symptoms were assessed according to the Brighton Collaboration case definition (BCCD) level.
During the period, there were 13 cases of vaccine-related anaphylaxis. The median age was 9 years (range, 1 month to 59 years). The incidence of anaphylaxis per million doses was 0.090 in 2005, 0.079 in 2012, 0.071 in 2013, 0.188 in 2015, and 0.036 in 2016. Of those cases, 23.1% were influenza vaccines, and 76.9% were BCCD level 2. Epinephrine was used in 46.2%.
Vaccine-related anaphylaxis seems to have been very rare in the past, but health care professionals must always be aware of anaphylaxis.


Vaccine; Vaccine; Anaphylaxis; Anaphylaxis; Adverse Reaction; Adverse Reaction; Vaccine Preventable Diseases; Vaccine Preventable Diseases
Full Text Links
  • JKMS
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error